Spots Global Cancer Trial Database for Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Official Title: Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Study ID: NCT04047862
Study Description
Brief Summary: The primary objectives of this study are : to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as Ociperlimab) in combination with tislelizumab in participants with advanced solid tumors in phase 1. Primary objective of Phase 1b is to assess overall response rate (ORR) determined by Investigator per RECIST v1.1 for patients in each dose- expansion cohort
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
St Vincents Hospital, Fitzroy, Victoria, Australia
Beijing Tongren Hospital, Cmu, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
Chongqing Cancer Hospital, Chongqing, Chongqing, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Jilin Cancer Hospital, Changchun, Jilin, China
The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, China
Jinan Central Hospital, Jinan, Shandong, China
Weifang Peoples Hospital, Weifang, Shandong, China
Shanghai Chest Hospital, Shanghai, Shanghai, China
Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, , Taiwan
Chung Shan Medical University Hospital, Taichung, , Taiwan
China Medical University Hospital, Taichung, , Taiwan
Veterans General Hospital Taichung, Taichung, , Taiwan
National Taiwan University Hospital, Taipei, , Taiwan
Taipei Tzu Chi Hospital, Taipei, , Taiwan
Linkou Chang Gung Memorial Hospital, Taoyuan, , Taiwan
Contact Details
Name: Study Director
Affiliation: BeiGene
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
